Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EKB-569 · 2 trials · 6 indications
| Name | Type | Description |
|---|---|---|
| EKB-569 | DRUG | - |
Inclusion Criteria: * Signed and dated, institutional review board (IRB) or independent ethics committee (IEC)-approved informed consent form before any protocol-specific screening procedures * Histologic and/or cytologic diagnosis of locally-advanced or metastatic non-small cell lung cancer in sub...
EKB-569 is an investigational small molecule being studied for the treatment of colorectal neoplasms and non-small-cell lung carcinoma. It has been evaluated in Phase 2 clinical trials for these oncology indications, though it remains in clinical development and is not approved.
EKB-569 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. The company has sponsored clinical trials of this investigational oncology drug.
EKB-569 is in Phase 2 clinical development. It has completed two Phase 2 trials, one in advanced non-small cell lung cancer and one in advanced colorectal cancer. The drug is investigational and has not been approved.
EKB-569 has been studied in two completed Phase 2 trials. NCT00067548 evaluated the drug in 44 patients with advanced non-small cell lung cancer, and NCT00072748 evaluated it in 63 patients with advanced colorectal cancer. Both trials enrolled adults aged 18 years and older.
EKB-569 is the primary name used for this investigational drug in clinical trial records. No alternative names have been reported for this compound in the available data.